Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/175055
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hutchings, Martin | - |
dc.contributor.author | Radford, John | - |
dc.contributor.author | Ansell, Stephen M. | - |
dc.contributor.author | Illés, Árpád | - |
dc.contributor.author | Sureda, Anna | - |
dc.contributor.author | Connors, Joseph M. | - |
dc.contributor.author | Sýkorová, Alice | - |
dc.contributor.author | Shibayama, Hirohiko | - |
dc.contributor.author | Abramson, Jeremy S. | - |
dc.contributor.author | Chua, Neil S. | - |
dc.contributor.author | Friedberg, Jonathan W. | - |
dc.contributor.author | Koren, Jan | - |
dc.contributor.author | Steward LaCasce, Ann | - |
dc.contributor.author | Molina, Lysiane | - |
dc.contributor.author | Engley, Gerald | - |
dc.contributor.author | Fenton, Keenan | - |
dc.contributor.author | Jolin, Hina | - |
dc.contributor.author | Liu, Rachel | - |
dc.contributor.author | Gautam, Ashish | - |
dc.contributor.author | Gallamini, Andrea | - |
dc.date.accessioned | 2021-03-15T07:58:30Z | - |
dc.date.available | 2021-03-15T07:58:30Z | - |
dc.date.issued | 2021-01-18 | - |
dc.identifier.issn | 0278-0232 | - |
dc.identifier.uri | http://hdl.handle.net/2445/175055 | - |
dc.description.abstract | Approximately one‐third of patients diagnosed with Hodgkin lymphoma presenting with Stage IV disease do not survive past 5 years. We present updated efficacy and safety analyses in high‐risk patient subgroups, defined by Stage IV disease or International Prognostic Score (IPS) of 4-7, enrolled in the ECHELON‐1 study that compared brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as first‐line therapy after a median follow‐up of 37.1 months. Among patients treated with A + AVD (n = 664) or ABVD (n = 670), 64% had Stage IV disease and 26% had an IPS of 4-7. Patients with Stage IV disease treated with A + AVD showed consistent improvements in PFS at 3 years as assessed by investigator (hazard ratio [HR], 0.723; 95% confidence interval [CI], 0.537-0.973; p = 0.032). Similar improvements were seen in the subgroup of patients with IPS of 4-7 (HR, 0.588; 95% CI, 0.386-0.894; p = 0.012). The most common adverse events (AEs) in A + AVD‐treated versus ABVD‐treated patients with Stage IV disease were peripheral neuropathy (67% vs. 40%) and neutropenia (71% vs. 55%); in patients with IPS of 4-7, the most common AEs were peripheral neuropathy (69% vs. 45%), neutropenia (66% vs. 55%), and febrile neutropenia (23% vs. 9%), respectively. Patients in high‐risk subgroups did not experience greater AE incidence or severity than patients in the total population. This updated analysis of ECHELON‐1 shows a favorable benefit‐risk balance in high‐risk patients. | - |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | John Wiley & Sons | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1002/hon.2838 | - |
dc.relation.ispartof | Hematological Oncology, 2021, Vol.39, num.2, p.185-195 | - |
dc.relation.uri | https://doi.org/10.1002/hon.2838 | - |
dc.rights | cc by-nd-nc (c) Hutchings, Martin et al., 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Malaltia de Hodgkin | - |
dc.subject.classification | Assaigs clínics | - |
dc.subject.classification | Pronòstic mèdic | - |
dc.subject.other | Hodgkin's disease | - |
dc.subject.other | Clinical trials | - |
dc.subject.other | Prognosis | - |
dc.title | Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: a prespecified subgroup analysis of high-risk patients from the ECHELON-1 study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 706956 | - |
dc.date.updated | 2021-03-15T07:58:30Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 33462822 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
706956.pdf | 482.88 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License